152 related articles for article (PubMed ID: 20715156)
1. Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma.
Loeb DM; Hobbs RF; Okoli A; Chen AR; Cho S; Srinivasan S; Sgouros G; Shokek O; Wharam MD; Scott T; Schwartz CL
Cancer; 2010 Dec; 116(23):5470-8. PubMed ID: 20715156
[TBL] [Abstract][Full Text] [Related]
2. Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma.
Senthamizhchelvan S; Hobbs RF; Song H; Frey EC; Zhang Z; Armour E; Wahl RL; Loeb DM; Sgouros G
J Nucl Med; 2012 Feb; 53(2):215-24. PubMed ID: 22251554
[TBL] [Abstract][Full Text] [Related]
3. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma.
Loeb DM; Garrett-Mayer E; Hobbs RF; Prideaux AR; Sgouros G; Shokek O; Wharam MD; Scott T; Schwartz CL
Cancer; 2009 Jun; 115(11):2514-22. PubMed ID: 19338063
[TBL] [Abstract][Full Text] [Related]
4. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
[TBL] [Abstract][Full Text] [Related]
5. Samarium for osteoblastic bone metastases and osteosarcoma.
Anderson P
Expert Opin Pharmacother; 2006 Aug; 7(11):1475-86. PubMed ID: 16859431
[TBL] [Abstract][Full Text] [Related]
6. Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP.
Pacilio M; Ventroni G; Basile C; Ialongo P; Becci D; Mango L
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):238-52. PubMed ID: 24077786
[TBL] [Abstract][Full Text] [Related]
7. 153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients.
Berger M; Grignani G; Giostra A; Ferrari S; Ferraresi V; Tamburini A; Cefalo G; Carnevale-Schianca F; Vassallo E; Picci P; Pagano M; Aglietta M; Pellerito RE; Fagioli F
Ann Oncol; 2012 Jul; 23(7):1899-905. PubMed ID: 22104576
[TBL] [Abstract][Full Text] [Related]
8. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma.
Franzius C; Bielack S; Flege S; Eckardt J; Sciuk J; Jürgens H; Schober O
Nuklearmedizin; 2001 Dec; 40(6):215-20. PubMed ID: 11797510
[TBL] [Abstract][Full Text] [Related]
9. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy.
Cameron PJ; Klemp PF; Martindale AA; Turner JH
Nucl Med Commun; 1999 Jul; 20(7):609-15. PubMed ID: 10423762
[TBL] [Abstract][Full Text] [Related]
10. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.
Anderson P; Nuñez R
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1517-27. PubMed ID: 18020921
[TBL] [Abstract][Full Text] [Related]
11. Clinical Efficacy and Safety Comparison of 177Lu-EDTMP with 153Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases.
Thapa P; Nikam D; Das T; Sonawane G; Agarwal JP; Basu S
J Nucl Med; 2015 Oct; 56(10):1513-9. PubMed ID: 26315829
[TBL] [Abstract][Full Text] [Related]
12. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
[TBL] [Abstract][Full Text] [Related]
13. An individual dosimetric approach to 153Sm-EDTMP therapy for pain palliation in bone metastases in correlation with clinical results.
Kendler D; Donnemiller E; Oberladstätter M; Erler H; Gabriel M; Riccabona G
Nucl Med Commun; 2004 Apr; 25(4):367-73. PubMed ID: 15097811
[TBL] [Abstract][Full Text] [Related]
14. Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.
Rodriguez V; Anderson PM; Litzow MR; Erlandson L; Trotz BA; Arndt CA; Khan SP; Wiseman GA
Leuk Lymphoma; 2006 Aug; 47(8):1583-92. PubMed ID: 16966270
[TBL] [Abstract][Full Text] [Related]
15. Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation.
Turner JH; Claringbold PG; Manning LS; O'Donoghue HL; Berger JD; Glancy RJ
J Natl Cancer Inst; 1993 Sep; 85(18):1508-13. PubMed ID: 8360933
[TBL] [Abstract][Full Text] [Related]
16. Intraorgan biodistribution and dosimetry of 153Sm-ethylenediaminetetramethylene phosphonate in juvenile rabbit tibia: implications for targeted radiotherapy of osteosarcoma.
Essman SC; Lewis MR; Miller WH
J Nucl Med; 2005 Dec; 46(12):2076-82. PubMed ID: 16330573
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma.
Anderson PM; Wiseman GA; Erlandson L; Rodriguez V; Trotz B; Dubansky SA; Albritton K
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6895-900. PubMed ID: 16203780
[TBL] [Abstract][Full Text] [Related]
18. ESR dosimetry of 89Sr and 153Sm in bone.
Kinoshita A; Braga FJ; Graeff CF; Baffa O
Appl Radiat Isot; 2001 Feb; 54(2):269-74. PubMed ID: 11200888
[TBL] [Abstract][Full Text] [Related]
19. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
20. Treatment of bone pain secondary to metastases using samarium-153-EDTMP.
Etchebehere EC; Pereira Neto CA; Lima MC; Santos Ade O; Ramos CD; Silva CM; Camargo EE
Sao Paulo Med J; 2004 Sep; 122(5):208-12. PubMed ID: 15558143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
